Navigation Links
Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer
Date:12/14/2010

autoimmune diseases, diabetes, and cancer by specifically modulating T cell activity.  The company's pipeline includes its lead candidate, otelixizumab, a targeted T cell immunomodulator in Phase 3 development for the treatment of type 1 diabetes that is partnered with GlaxoSmithKline.  Tolerx's product candidate, TRX518, is a targeted T cell immunotherapy in Phase 1 development for the treatment of cancer. TRX1, a Phase 1 candidate, is a nonlytic anti-CD4 antibody that is being developed for the treatment of aberrant or untoward immune responses.  The company also has two preclinical candidates, TRX585, and TRX385, which enhance immune responses and as such are being evaluated for potential benefit in the treatment of cancer and chronic infections. Tolerx is a privately held company headquartered in Cambridge, MA USA.  For more information, please visit www.tolerx.com.


'/>"/>
SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDFs 20th World Diabetes Congress
2. Tolerx Announces Amendment to Phase 3 DEFEND Protocol
3. Tolerx Expands Phase 3 DEFEND Trial of Otelixizumab in Europe
4. Laureate Announces Manufacturing Agreement with Tolerx
5. Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety
6. GeNO LLC Initiates Phase 2 Trial For Nitric Oxide Delivery System
7. SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK
8. Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
9. Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing
10. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
11. Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Calif., Sept. 2 Accuray,Incorporated (Nasdaq: ARAY ), ... an Investor and Analyst Meeting in Boston, Mass. on ... PDT). This meeting will,coincide with the 50th Annual Meeting ... A live webcast of the presentation will be ...
... NOVATO, Calif., Sept. 2 BioMarin,Pharmaceutical Inc. (Nasdaq: ... of BioMarin, will present a company,update at the Morgan ... September 9, 2008 at 1:35 p.m. ET., Interested ... conference,call via the investor section of the BioMarin website, ...
... DIEGO, Sept. 2 NuVasive, Inc. (Nasdaq:,NUVA), a ... disruptive surgical treatments for the spine, announced today,that ... Kevin,O,Boyle, Executive Vice President and Chief Financial Officer, ... Healthcare Unplugged,Conference at the Grand Hyatt New York ...
Cached Biology Technology:Accuray Incorporated to Host Investor and Analyst Meeting at ASTRO 2BioMarin to Present at the Morgan Stanley Global Healthcare Conference 2NuVasive to Present at Morgan Stanley Global Healthcare Unplugged Conference 2NuVasive to Present at Morgan Stanley Global Healthcare Unplugged Conference 3
(Date:12/11/2014)... Dec. 10, 2014  Data Sciences International (DSI), ... released a new series of digital telemetry implants ... researchers. M series, part of the PhysioTel™ Digital ... best possible physiologic data when incorporating functional endpoints ... endpoints to toxicology studies has evolved from short ...
(Date:12/10/2014)... RALEIGH, N.C. , Dec. 9, 2014  Valencell, ... announced it is seeing a staggering demand from its ... demand, the Company revealed, is not solely coming from ... industries as well. "A wearable is only ... a result, accuracy is the ultimate driver in long-term ...
(Date:12/10/2014)... CIE San Diego has launched an innovative ... tissue that enhances care coordination among social service and ... information; earned a second $1 million grant from the ... aging in community and; will be recognized as a ... 4-6p. CIE San Diego today announced ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... genetic modification to successfully manipulate the growth in height of ... look similar to normal trees – but after several years ... a few inches. , This is a “proof of concept” ... techniques. It opens the door to a wide variety of ...
... discovery of a mechanism by which Mycobacterium avium – ... and is prevalent in emphysema and AIDS patients among ... compromises the body’s immunity. , Results of the study, ... published online this week in the Proceedings of the ...
... researchers helps explain how “memory” T cells protect the ... in Proceedings of the National Academy of Science Online ... where immune cells reside and proliferate, but also are ... of an invading virus occurs. , After becoming sick ...
Cached Biology News:Researchers demonstrate way to control tree height 2Researchers demonstrate way to control tree height 3Researchers discover 'acquired' DNA key to certain bacterial infection 2How 'memory' T cells curb the spread of viruses throughout the body 2
...
...
Rb anti-Occludin (C-term GST)...
... siRNA and miRNA Isolation Traditional ... recover mRNA and can result in the ... Ambions mirVana miRNA Isolation Kit purifies all ... and double-stranded. Through an enrichment procedure included ...
Biology Products: